Citations

Clear

3042 citation(s) found for "Kumar, S".

Renovascular disease induces functionally relevant, locus-specific alterations to DNA methylation and hydroxymethylation in swine scattered tubular-like cells
Iyer, Vinaya C., Shivam, Kumar, Kazeminia, Sara , Zhu, Xiang-Yang, Tang, Hui, Xue, Ailing, Chade, Alejandro , Lerman, Lilach O. , Herrmann, Sandra, Irazabal, Maria V , Lerman, Lilach O , Eirin, Alfonso , Kazeminia, Sara , Herrmann, Sandra M. , Irazabal, María V. , Eirin, Alfonso

Mayo Clinic

American Journal of Physiology-Renal Physiology | July 2, 2026 | Volume: 331 | Issue: 2 | Pages: F213-F224

10.1152/ajprenal.00055.2026 | PMID 42390182 Get It

Scattered tubular-like cells (STCs) are dedifferentiated renal tubular cells that repair other damaged kidney cells. This study shows that renovascular disease (RVD) induces site-specific 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) modifications in DNA associated with transcriptional changes and impaired proliferative capacity of swine STCs, which could be mitigated in RVD-STCs treated with an epigenetic modulator. Therefore, our observations may contribute to the development of novel approaches to preserve the reparative capacity of STCs in individuals with RVD.
Late-onset symmetric cervical and upper thoracic lipomatosis as a presenting manifestation of mitochondrial disorder
Muniswamy, Jai Kumar Rajavoor , Dewey, Daniel Campbell, Muthusamy, Karthik , Rajavoor Muniswamy, Jai Kumar , Muthusamy, Karthik

Mayo Clinic

BMJ Case Reports | July 1, 2026 | Volume: 19 | Issue: 7 | Pages: e272707

10.1136/bcr-2026-272707 | PMID 42386330 Get It

Weight Changes in Children and Adolescents with Epilepsy and Overweight/Obesity Treated with Zonisamide
Salama, Mostafa , Touma, Elsie, Hassan, Doha , Wong-Kisiel, Lily, Keating, Gesina, Kumar, S, Salama, Mostafa , Keating, Gesina F.

Mayo Clinic

Childhood Obesity | June 27, 2026 | Volume: 22 | Issue: 7 | Pages: 457-465

10.1177/21532176261461791 | PMID 42363812 Get It

Objective: To examine changes in weight status after initiating zonisamide in children with epilepsy and elevated body mass index (BMI). Study Design: Retrospective chart review of children aged 2 to ≤18 years with epilepsy treated with zonisamide, assessing BMI changes over 2 years. Results: A total of 140 children were included; mean age (SD) at initiation was 9.60 years (3.93). BMI categories included 28 children with severe obesity, 28 with mild–moderate obesity, 28 with overweight, and 56 with healthy weight. Participants were 56.6% female, 91.4% non-Hispanic/Latino, and 88.6% White. At 2 years, BMI z score decreased significantly across all BMI groups: severe obesity −0.38 ( N = 13, 95% CI −0.64 to −0.13; p = 0.003), mild-moderate obesity −0.39 ( N = 15, 95% CI −0.62 to −0.16; p = 0.001), overweight −0.60 ( N = 14, 95% CI −0.84 to −0.36; p < 0.001), and healthy weight −0.46 ( N = 21, 95% CI −0.63 to −0.28; p < 0.001). Significant BMI z score reductions were also observed across age groups: 2–10 years −0.48 ( N = 40, 95% CI −0.62 to −0.34), >10–13 years −0.27 ( N = 15, 95% CI −0.50 to −0.04), and ≥13 years −0.63 ( N = 12, 95% CI 0.89 to −0.36). Conclusions: BMI reduction persisted up to 2 years following zonisamide initiation in children with epilepsy. Further prospective studies are needed to evaluate the weight loss effect and safety of zonisamide in children with epilepsy and elevated BMI.
MYH11 ‐Related Hereditary Type 2 Visceral Myopathy in a Large Kindred: Diagnostic Odyssey With Milder Clinical Manifestations
Muniswamy, Jai Kumar Rajavoor , Zele, Elise Van, Agely, Ali , Muthusamy, Karthik , Van Zele, Elise, Muthusamy, Karthik , Rajavoor Muniswamy, Jai Kumar

Mayo Clinic

American Journal of Medical Genetics Part A | June 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70235 | PMID 42362996 Get It

ABSTRACT MYH11 ‐related hereditary type 2 visceral myopathy is a rare smooth muscle disorder typically presenting in infancy with severe gastrointestinal and genitourinary dysfunction. We describe a 73‐year‐old female with lifelong symptoms of gastrointestinal and urinary dysfunction, including chronic constipation, neurogenic bladder, recurrent urinary tract infections, gastroparesis, and pelvic organ prolapse. A multigenerational family history revealed similar visceral smooth muscle abnormalities among 14 affected individuals over five generations, suggesting autosomal dominant inheritance. Whole‐genome sequencing identified a heterozygous, likely pathogenic variant in MYH11 c.5819del; p.(Pro1940HisfsTer91), consistent with the diagnosis of autosomal dominant type 2 visceral myopathy. This variant causes production of an abnormally elongated myosin‐heavy chain, disrupting muscle contractile function. This individual's survival into her eighth decade reflects long‐term clinical stability, possibly attributable to the variant's milder effect. We describe the clinical course of the disease, along with a comprehensive review of previously described individuals with the same variant. This case broadens the phenotypic spectrum of MYH11 ‐associated visceral myopathy, demonstrating that late‐onset, milder forms can occur and remain compatible with long‐term survival with optimal supportive management. Comprehensive genetic evaluation identifies primary disorders, enabling precise diagnosis, tailored management, and informed genetic counseling for complex phenotypes.
Proprioceptive Stimuli as a Trigger for Leucine-Rich Glioma-Inactivated-1 (LGI1) IgG Associated Autoimmune Seizures, a Case Report
Gupta, Ashutosh , Holmes, Miles D., Dubey, Divyanshu, Omidi, Shirin Jamal, Goyal, Megan, Sriwastava, Shitiz, Gupta, Rajesh , Gupta, Ashutosh , Gupta, Rajesh Kumar , Dubey, Divyanshu , Goyal, Megan, Sriwastava, Shitiz

Mayo Clinic

The Neurohospitalist | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19418744261463745 | PMID 42368480 Get It

Leucine-rich glioma-inactivated-1 (LGI1) IgG-associated autoimmune encephalitis typically presents with faciobrachial dystonic seizures, hyponatremia, and temporal lobe MRI abnormalities. However, the clinical spectrum of LGI1 IgG-associated AE extends beyond these classical features, with reports of diverse seizure semiologies and atypical presentations challenging traditional diagnostic paradigms. This study reports a male in his late 60s presenting with recurrent episodes of right foot cramping and electric shock-like pain, progressing to generalized tonic-clonic seizures. Initial workup suggested chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but LGI1 IgG antibodies were subsequently detected. Despite treatment with intravenous immunoglobulin (IVIG), the seizures persisted. This case highlights the heterogeneity in LGI1 encephalitis presentations. The patient’s proprioceptive-induced reflex seizures represent a rare manifestation of the disease. Treatment with rituximab, a B-cell depleting therapy, resulted in significant improvement, suggesting its potential effectiveness in LGI1 encephalitis with a resistant seizure course. The case also emphasizes the intricate interplay between the mesial temporal lobe, basal ganglia, and frontal regions in LGI1 encephalitis pathophysiology.
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Lim, Kenneth J C , Kumar, Shaji, Chhabra, Saurabh , Tan, Melinda Si Yun , Dooley, Katharine, Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Kourelis, Taxiarchis, Warsame, Rahma, Abdallah, Nadine , Bergsagel, P. Leif, Yadav, Udit, Geyer, Susan M. , Ailawadhi, Sikander, Lin, Yi, Zanwar, Saurabh , Chhabra, Saurabh , Tan, Melinda , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Wiedmeier-Nutor, Julia E , Geyer, Susan , Rajkumar, S Vincent , Fonseca, Rafael , Zanwar, Saurabh S , Lim, Kenneth J C , Kumar, Shaji , Parrondo, Ricardo D , Dooley, Katharine , Stephens, H. J. B., Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Rajkumar, S. Vincent , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | June 26, 2026 | Volume: 101 | Issue: 9 | Pages: 2269-2279

10.1002/ajh.70425 | PMID 42351384 Get It

ABSTRACT Ciltacabtagene autoleucel (cilta‐cel) has demonstrated excellent efficacy and long‐term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard‐of‐care cilta‐cel across the three Mayo clinic centers. Patients with a follow‐up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure ( n = 52), 69% had progressive disease and 31% had a non‐relapse mortality (NRM) event. In patients without early treatment failure ( n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA‐directed therapy, presence of extramedullary disease and a CAR‐HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta‐cel in earlier lines of treatment (1–3 vs. 4 or more) demonstrated comparable PFS (12‐month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high‐risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high‐risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.
Cerebrospinal Fluid Shunts: An Updated Radiologic Review of Devices, Malfunctions, and Complications
Singh, Ishaan , Goyal, Nikita, Rai, Pranjal , Mehta, P. , Agarwal, Amit , Singh, Annie , Singh, Ishaan , Goyal, Nikita , Rai, Pranjal , Mehta, Parv , Agarwal, Amit Kumar

Mayo Clinic

Korean Journal of Radiology | June 26, 2026 | Volume: 27 | Issue: 8 | Pages: 728

10.3348/kjr.2025.1660 | PMID 42366028 Get It

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement
Xiao, Alexander , Zanwar, Saurabh , Lin, Yi, Kapoor, Prashant , Abdallah, Nadine , Baudi, Francis, Dingli, David, Gertz, Morie A. , Gonsalves, Wilson I, Hayman, Suzanne R. , Kourelis, Taxiarchis , Tan, Melinda SY, Warsame, Rahma , Rajkumar, S Vincent, Kumar, Shaji , Dingli, David , Buadi, Francis K. , Lin, Yi , Lin, Yi , Buadi, Francis K , Binder, Moritz , Dispenzieri, Angela , Dingli, David , Gertz, Morie A , Gonsalves, Wilson , Kourelis, Taxiarchis , Leung, Nelson , Muchtar, E , Siddiqui, Mustaqeem A , Tan, Melinda , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Xiao, Alexander H , Binder, Moritz , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Muchtar, Eli , Siddiqui, Mustaqeem , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: 10 | Issue: 17 | Pages: 5828-5833

10.1182/bloodadvances.2026020668 | PMID 42348786 Get It

Abstract Extramedullary disease (EMD) is increasingly recognized in relapsed/refractory multiple myeloma (MM), with central nervous system involvement (CNS-MM) representing a rare but highly aggressive manifestation associated with dismal outcomes. Data on its incidence and optimal management, particularly in the era of cellular and bispecific therapies, remain limited. We conducted a retrospective analysis of patients with MM with pathology-confirmed EMD treated at our institution between January 2000 and December 2023. CNS-MM was defined by parenchymal or leptomeningeal involvement. Clinical features, cytogenetics, treatments, and outcomes were analyzed, with predictors of CNS involvement evaluated among patients with EMD. Among 304 patients with EMD, 20 (6.5%) had CNS-MM. CNS involvement occurred a median of 19.2 months after MM diagnosis, though 15% presented at diagnosis. CNS-MM was strongly associated with high-risk cytogenetics (odds ratio [OR], 3.7) and additional visceral EMD (OR, 4.6). Median overall survival (OS) from CNS-MM diagnosis was 4.2 months. Outcomes were significantly improved in patients receiving chimeric antigen receptor T-cell therapy or bispecific antibodies, with a median OS of 19.2 months vs 1.2 months in those who did not receive immune effector therapies. Intrathecal (IT) chemotherapy demonstrated limited and transient benefit. In conclusion, CNS-MM is an aggressive complication enriched in high-risk, multifocal EMD with extremely poor prognosis. Cellular and bispecific therapies show promising activity and may meaningfully improve survival, whereas IT therapy appears to have limited efficacy. Prospective studies are needed to define optimal treatment strategies for CNS-MM.
Subclinical primary aldosteronism and major adverse cardiovascular events: evidence for a continuum of renin-independent aldosterone excess and a proposal for early detection
Akoum, Atef , Hakim, Mounir, Kwayess, Rola , Wehbeh, Bahaa El Deen , Alaaeddine, Lina, Shabrawi, Mohamed Nasser El, Das, Ashesh , Kumar, Akshay , Rebeiz, Abdallah, Li, J M, Elshabrawi, Mohamed Nasser , Avula, Sreekant , Rebeiz, Abdallah

Mayo Clinic

Frontiers in Cardiovascular Medicine | June 23, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1826678 | PMID 42415983 Get It

Background Primary aldosteronism (PA), a renin-independent state of aldosterone excess, is associated with excess risk of stroke, myocardial infarction, atrial fibrillation, heart failure, and chronic kidney disease compared with essential hypertension. Emerging evidence suggests that renin-independent aldosterone excess exists on a continuum rather than as a dichotomous disease state, including subclinical primary aldosteronism (sPA), even in normotensive individuals. Whether sPA is associated with major adverse cardiovascular events (MACE) prior to overt hypertension remains incompletely characterized. Objective To synthesize available evidence linking renin suppression and mild aldosterone excess to cardiovascular outcomes. Methods A narrative review of the literature was conducted using PubMed/MEDLINE, the Cochrane Library, and Web of Science from inception through May 2025, to identify cohort studies evaluating renin phenotype, aldosterone levels, and cardiovascular outcomes. Results Suppressed renin and higher aldosterone levels, even within conventionally normal ranges, are associated with incident hypertension, left ventricular hypertrophy (LVH), atrial fibrillation, and cardiovascular events. In overt PA, significantly higher rates of cardiovascular diseases have been observed compared with blood pressure-matched essential hypertension. Emerging population-based data suggest a graded cardiovascular risk extending below traditional diagnostic thresholds. Conclusion Biochemical phenotypes consistent with sPA may represent an early cardiometabolic state associated with elevated risk of MACE, even before overt PA criteria are met. The absence of standardized diagnostic thresholds and randomized interventional data currently limits clinical translation. Prospective trials evaluating renin-guided screening and early mineralocorticoid receptor antagonism are needed to determine whether intervention at the subclinical stage reduces long-term cardiovascular harm.
Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Kharfan-Dabaja, Mohamed A., Uyanik, Mehmet S., Sher, Taimur , Qin, Hong, Aljurf, Mahmoud, Kumar, A, Kharfan‐Dabaja, Mohamed A. , Tsalatsanis, Athanasios , Uyanik, Mehmet, Qin, Hong, Aljurf, Mahmoud , Chavez, Julio C

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | June 23, 2026 | Volume: 19 | Issue: 1 | Pages: 37-43

10.4103/hemoncstem.hemoncstem-d-26-00018 | PMID 42333073 Get It

Background: A diagnosis of cancer creates a stressful situation owing to the uncertainties related to the thought of possible suffering from complications associated with treatment toxicities, the fear of not responding to the prescribed treatment, or death. The prevalence of mental health disorders is relatively higher in cancer patients vis-à-vis the general population. Methods: We performed a retrospective cohort study to evaluate the impact of mental health disorders on outcomes of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR T-cell) therapy using data from the TriNetX research network. Results: A total of 1587 patients met the inclusion criteria (858 with a mental health diagnosis and 729 without). After propensity score matching for age and gender, 1320 patients were included in the analysis (660 in each group). The 1-year OS was higher in patients without a mental health disorder (76.0% versus 69.4%, P = 0.004). Patients with mental health disorders had a higher incidence of cytokine release syndrome (all grades) compared with those without (35.5% versus 27.6%, P < 0.001) and immune effector cell-associated neurotoxicity syndrome (all grades) (16.8% versus 10.1%, P < 0.001). Conclusions: These findings emphasize the importance of thorough psychiatric evaluation and management in patients receiving CAR T-cell therapy. Patients with mental health disorders may need significant assistance with coordinating medical services to better adhere to required care management. Future studies are needed to help determine whether preventive and real-time mental health interventions can favorably impact outcomes of these patients.